Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of Nivolumab in previously treated (cohorts, A, B \& C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma participants.


Options:
A: Arm Label: Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: MEL: Pembrolizumab 10 mg/kg Q2W (Part B); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): MEL: Pembrolizumab 10 mg/kg Q2W (Part B), MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D), MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D), NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F), NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled), NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F), NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled), Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1), Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A), Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2), Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)
B: Arm Label: Nivolumab (Cohort A, B, C and D); Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Doxorubicin, Drug: Vinblastine, Drug: Dacarbazine | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Vinblastine; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Nivolumab (Cohort A, B, C and D)
C: Arm Label: Brentuximab Vedotin + Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: brentuximab vedotin, Drug: nivolumab | Intervention Type: DRUG; Name: brentuximab vedotin; Assigned to Arm(s): Brentuximab Vedotin + Nivolumab | Intervention Type: DRUG; Name: nivolumab; Assigned to Arm(s): Brentuximab Vedotin + Nivolumab
D: Arm Label: Nivolumab monotherapy (Dose Escalation); Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab + Lirilumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Lirilumab | Arm Label: Nivo + Dara + Pom + Dexa vs. Nivo + Dara; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone | Arm Label: Daratumumab vs. Nivolumab + Daratumumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara, Nivolumab + Ipilimumab, Nivolumab + Lirilumab, Nivolumab monotherapy (Dose Escalation) | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: BIOLOGICAL; Name: Lirilumab; Assigned to Arm(s): Nivolumab + Lirilumab | Intervention Type: BIOLOGICAL; Name: Daratumumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Pomalidomide; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara

Answer: B